Eli Lilly and Company (NYSE:LLY) EVP Sells 5,000 Shares of Company Stock

Eli Lilly and Company (NYSE:LLY) EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the sale, the executive vice president owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Anat Hakim also recently made the following trade(s):

• On Friday, August 7th, Anat Hakim sold 5,000 shares of Eli Lilly and Company stock. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00.

Eli Lilly and Company Stock Down 0.2%

Shares of LLY traded down $2.31 during mid-day trading on Tuesday, reaching $1,408.68. The company’s stock had a trading volume of 2,712,512 shares, compared to its average volume of 2,947,000. The business has a fifty day moving average of $1,200.81 and a 200 day moving average of $1,094.25. The company has a market cap of $1.33 trillion, a price-to-earnings ratio of 45.72, a price-to-earnings-growth ratio of 1.73 and a beta of 0.40. Eli Lilly and Company has a 1 year low of $850.51 and a 1 year high of $1,449.68. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. The business had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. Eli Lilly and Company’s revenue for the quarter was up 38.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $7.02 earnings per share. As a group, analysts forecast that Eli Lilly and Company will post 35.18 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. Eli Lilly and Company’s dividend payout ratio is currently 22.46%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on LLY. UBS Group increased their price target on shares of Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the company a “buy” rating in a report on Friday. Scotiabank lifted their target price on Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the stock a “sector outperform” rating in a research report on Friday. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the company an “overweight” rating in a research note on Friday. Citigroup upped their price target on Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the company a “buy” rating in a report on Friday. Finally, Weiss Ratings downgraded Eli Lilly and Company from a “buy (b+)” rating to a “buy (b)” rating in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,404.14.

Institutional Trading of Eli Lilly and Company

Several institutional investors have recently made changes to their positions in the business. BlackRock Inc. grew its holdings in shares of Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after purchasing an additional 1,046,558 shares during the last quarter. State Street Corp lifted its holdings in Eli Lilly and Company by 1.7% during the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after purchasing an additional 605,752 shares during the last quarter. Bank of America Corp DE bought a new position in Eli Lilly and Company during the 2nd quarter valued at about $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Eli Lilly and Company by 1.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock valued at $8,647,153,000 after purchasing an additional 137,364 shares during the last quarter. Finally, Jennison Associates LLC boosted its position in Eli Lilly and Company by 7.9% in the second quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock valued at $6,550,587,000 after buying an additional 400,538 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s third-quarter revenue of $24.4 billion and EPS of $7.48 topped analyst estimates. The company also raised its full-year revenue guidance to $91 billion–$92 billion, reinforcing expectations for continued growth. Article: Raised Guidance Altering The Investment Case For Eli Lilly Stock?
• Positive Sentiment: Demand for Mounjaro and Zepbound remains a major growth driver. A report also highlighted Phase 3 results in which experimental retatrutide outperformed Ozempic 2 mg in a diabetes trial, potentially strengthening Lilly’s competitive position if further development succeeds. Article: Eli Lilly Just Gained 22% in a Month
• Positive Sentiment: Analyst optimism adds support: Morgan Stanley raised its price target amid surging demand for Lilly’s weight-loss drugs, and Cantor Fitzgerald raised its target to $1,600 while maintaining an Overweight rating. Article: Unprecedented weight-loss drug craze pushing Lilly to near-record highs
• Neutral Sentiment: Lilly continues to invest beyond obesity and diabetes, including in oncology and AI-supported Alzheimer’s research, but its broader pipeline has also seen candidates discontinued. The long-term payoff is uncertain. Article: Lilly’s R&D whirlwind
• Negative Sentiment: Some coverage cautions that the shares’ sharp run-up leaves little room for disappointment. Lilly’s reliance on its leading GLP-1 products, signs of slower future revenue growth, and falling realized drug prices could weigh on the investment case. Article: Eli Lilly Jumped 6% After Earnings

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.